BRIEF-Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

June 5 (Reuters) - Bayer AG BAYGn.DE:

  • PHASE III FIND‑CKD RESULTS SHOW BAYER’S KERENDIA® (FINERENONE) IMPROVED EGFR SLOPE AND REDUCED RISK OF A COMPOSITE KIDNEY-CARDIOVASCULAR OUTCOME IN ADULTS WITH NON‑DIABETIC CHRONIC KIDNEY DISEASE

  • BAYER AG - KERENDIA MEETS PRIMARY ENDPOINT WITH SIGNIFICANT REDUCTION IN KIDNEY DISEASE PROGRESSION

  • BAYER AG - KERENDIA SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES; SERIOUS ADVERSE EVENTS 20.9% VERSUS 21.2% PLACEBO

  • BAYER AG - KERENDIA REDUCES RISK OF COMPOSITE KIDNEY-CARDIOVASCULAR OUTCOME VERSUS PLACEBO

Source text: ID:nBw6wPtQ3a

Further company coverage: [BAYGn.DE]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.